Aim: Adalimumab is an effective treatment for Crohn's disease (CD). We aimed to describe the early patterns of use, efficacy and response to adalimumab in four regions of New Zealand.
Methods: Prospectively collected CDAI data were used to examine adalimumab continuation rates in CD patients.